Contribute Try STAT+ Today

Pfizer has accused a former global marketing director of misappropriating “confidential and extremely sensitive information” when she voluntary left the drug maker last month, according to a lawsuit filed in federal court on Tuesday.

In the lawsuit, Pfizer claims that Aimee De Blasis Amann had forwarded strategic plans, short- and long-term operating plans, and “specific product launch roadmaps” in 42 emails to her unsecured personal account during the weeks leading up to her voluntary departure on Jan. 13. The drug maker also claims she “secretly copied” about 600 files to an external hard drive within 24 hours of resigning.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • A new spin on the ‘Data Integrity’ problem. The unspoken issue is how long did it take to notice this? And why wasn’t the e-mail pattern detected sooner? ‘Just asking …’

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy